The paradox at the heart of the work is one that has fascinated cancer biologists for years: although reactive oxygen species, or ROS, are often painted as molecular vandals that damage DNA and drive tumor formation, cancer cells actually live dangerously close to the edge of oxidative tolerance. Having adapted to a certain baseline of ROS, they depend heavily on antioxidant defenses to keep levels from tipping into lethal territory. Pushing ROS past that threshold has therefore emerged as a promising therapeutic concept, and the Nanchang team set out to test whether p-coumaric acid could serve as the tipping force.

In a battery of in vitro experiments, the researchers exposed hepatocellular carcinoma cells to the compound and measured its effects on growth, proliferation, migration, and survival. The results were unambiguous. p-Coumaric acid significantly inhibited the growth and proliferation of the cancer cells, impeded their ability to migrate in wound healing and Transwell assays, and triggered the characteristic physical hallmarks of programmed cell death, including cell shrinkage. Flow cytometry confirmed that the treated cells were dying by apoptosis, and further analysis showed that the compound suppressed the levels of anti-apoptotic and pro-proliferative proteins that liver cancer cells rely on to survive.

The mechanistic story, however, is where the study becomes technically compelling. Using measurements of mitochondrial function, the team found that p-coumaric acid reduced the mitochondrial membrane potential and cut ATP production in the cancer cells. This energetic collapse is significant because mitochondria are both the power plants of the cell and a major source of ROS: when the electron transport chain is disrupted, electrons leak and combine with oxygen to form superoxide and related reactive species. By destabilizing mitochondrial function, the compound effectively opened the floodgates for endogenous ROS accumulation, drowning the cancer cells in their own reactive byproducts.

The researchers then turned their attention to the cell’s principal antioxidant safety valve, the Nrf2 signaling pathway. Nrf2, or nuclear factor erythroid 2-related factor 2, is a transcription factor that, when activated, switches on a broad program of antioxidant and detoxification genes, including heme oxygenase-1, or HO-1. In many tumors, Nrf2 is constitutively active, granting cancer cells remarkable resistance to oxidative stress and to chemotherapy. The team found that p-coumaric acid inhibits this pathway in liver cancer cells, removing a critical layer of protection and allowing ROS levels to climb even higher. The compound thus attacks from two directions at once: it boosts ROS production through mitochondrial dysfunction while simultaneously dismantling the defenses that would normally neutralize it.

To confirm that the Nrf2 arm of the mechanism was genuinely responsible for part of the effect, the researchers used hemin, an agonist of the antioxidant enzyme HO-1. When hemin was applied, it counteracted the inhibitory effect of p-coumaric acid on the viability of the cancer cells, demonstrating that re-engaging the antioxidant machinery could rescue the tumor cells from the oxidative assault. This pharmacological rescue experiment strengthens the causal chain linking Nrf2 inhibition, ROS accumulation, and cell death, rather than leaving the pathway as a mere correlation observed in treated cells.

The in vivo evidence proved equally persuasive. Using a subcutaneous xenograft mouse model of hepatocellular carcinoma, the team showed that p-coumaric acid suppressed tumor growth in living animals. Crucially, when the mice were also treated with N-acetylcysteine, a well-established ROS scavenger, the anti-cancer effects of the compound were reversed. This is the kind of result that carries real weight in redox biology: if mopping up reactive oxygen species abolishes the therapeutic effect, then ROS accumulation is not a side effect but the engine of the compound’s anti-tumor activity. The N-acetylcysteine experiment therefore serves as the linchpin connecting the cellular mechanism to the whole-animal outcome.

The findings also sit within a growing body of literature on p-coumaric acid, a compound already known for anti-inflammatory, antioxidant, and protective effects in contexts ranging from diabetic kidney disease to lung inflammation. Earlier work had hinted at anti-cancer potential, including studies showing apoptotic effects in colon cancer cells and cytotoxicity in neuroblastoma cells through ROS-mediated mitochondrial dysfunction, as well as nanoparticle delivery strategies for breast cancer therapy. What distinguishes the new study is its systematic dissection of the compound’s action in hepatocellular carcinoma specifically, a cancer for which treatment options remain limited and recurrence rates remain high, and its dual demonstration of mitochondrial and Nrf2-targeted mechanisms backed by in vivo validation.

The broader implications are twofold. First, the work reinforces the emerging view that redox homeostasis is a pivotal regulator of liver cancer progression and that deliberately disrupting it is a viable therapeutic strategy, one shared by other natural products and by synthetic agents designed to induce oxidative stress in tumors. Second, it suggests that p-coumaric acid, a cheap and widely available dietary molecule with a favorable safety profile in other contexts, could be developed further as a lead compound, whether administered directly, formulated into targeted delivery systems, or combined with existing therapies to sensitize tumors. The authors, led by Jiahao Zheng and corresponding author Yange Liu of the School of Basic Medical Sciences at Nanchang University, caution that the findings come from cell culture and mouse models, and that translating them into clinical practice will require pharmacokinetic studies, dosing optimization, and eventually human trials. Still, the study adds a compelling entry to the pharmacopeia of plant-derived molecules under investigation for cancer therapy, and it underscores a lesson that modern oncology keeps relearning: sometimes the most effective way to kill a cancer cell is not to poison it directly, but to strip away its defenses and let the chemistry it cannot escape do the rest.

Subject of Research: The anti-cancer effects and ROS-based mechanism of p-coumaric acid in hepatocellular carcinoma

Article Title: p-Coumaric acid inhibits hepatocellular carcinoma through promoting ROS accumulation

Article References: Zheng, J., Zhang, Q., Wang, L., Yuan, M., Wang, Y., Wei, X., Lian, H., Liu, X., & Liu, Y. (2026). p-Coumaric acid inhibits hepatocellular carcinoma through promoting ROS accumulation. Medical Oncology, 43(10), Article 279. https://doi.org/10.1007/s12032-026-03367-7

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03367-7

Keywords: p-coumaric acid, hepatocellular carcinoma, reactive oxygen species, Nrf2 pathway, mitochondrial dysfunction, apoptosis, liver cancer, oxidative stress, natural compounds, HO-1, N-acetylcysteine, cancer therapy

Copper is required for the activity of several enzymes involved in energy production, antioxidant defense, connective-tissue formation and cellular signaling. The liver plays a central role in controlling the body’s copper balance, absorbing the metal from the diet, incorporating it into proteins and directing excess copper toward biliary excretion. This system depends on a network of transporters and binding proteins. Copper transporter 1, or CTR1, helps cells import copper, while ATP7A and ATP7B distribute it to intracellular destinations or remove it when levels rise. Ceruloplasmin carries much of the copper in the bloodstream, and additional chaperone proteins deliver the metal to specific enzymes. In healthy tissue, this carefully regulated traffic prevents copper from accumulating in its reactive, chemically dangerous form.

Cancer can disrupt that balance. Tumor cells often remodel nutrient uptake and energy production to sustain rapid proliferation, and copper appears to be part of this metabolic adaptation. The review highlights evidence that hepatocellular carcinoma may exploit the copper–MYC–CTR1 axis. MYC, a transcription factor frequently activated in cancer, can increase the expression of genes that support proliferation and metabolism, including pathways that influence copper uptake. Elevated CTR1 may consequently provide malignant cells with more copper, potentially supporting enzymes involved in mitochondrial respiration, antioxidant protection and signaling. At the same time, excessive or improperly localized copper can generate reactive oxygen species, damage proteins and membranes, and place severe pressure on the endoplasmic reticulum and mitochondria.

The most intriguing development is cuproptosis, a copper-dependent form of regulated cell death first described in 2022. Unlike apoptosis, which involves caspase activation and controlled cellular dismantling, cuproptosis is closely tied to mitochondrial metabolism and protein lipoylation. Lipoylation is a biochemical modification in which a lipoate group is attached to specific lysine residues on enzymes of the tricarboxylic acid cycle. These modified proteins are essential for processing nutrients and producing energy inside mitochondria. When copper enters susceptible cells in excessive amounts, it can bind directly or indirectly to lipoylated mitochondrial proteins, promoting their aggregation. At the same time, copper can destabilize iron–sulfur proteins, leading to proteotoxic stress and ultimately cell death.

This mechanism creates a possible distinction between tumor cells and normal cells. Many cancers depend heavily on mitochondrial respiration or retain active tricarboxylic acid-cycle pathways, making them potentially sensitive to copper-induced mitochondrial damage. The review discusses research showing that ARID1A-deficient hepatocellular carcinoma may be especially vulnerable when the TCA cycle is targeted through cuproptosis. ARID1A is a component of the chromatin-remodeling machinery, and its loss can alter gene expression, metabolism and stress responses. In experimental models, this genetic defect was associated with a metabolic weakness that could be exploited to produce synthetic lethality, a situation in which blocking one pathway is particularly destructive only when a second vulnerability is already present.

Copper’s effects in liver cancer are not limited to direct toxicity. The metal can influence angiogenesis, the process through which tumors build new blood vessels. Research cited in the review connects copper transport and copper-dependent signaling with vascular endothelial growth factor pathways, including VEGFR2 signaling. Because growing tumors require oxygen and nutrients, changes in copper availability may affect not only cancer-cell metabolism but also the surrounding blood-vessel network. Copper can also interact with inflammatory signaling, antioxidant systems and the tumor microenvironment. These effects may influence immune-cell behavior, stromal remodeling and the capacity of malignant cells to invade nearby tissue.

The therapeutic possibilities are therefore moving in two opposite directions. One strategy is to increase copper stress inside cancer cells. Copper ionophores such as elesclomol can transport copper across membranes and direct it toward mitochondria, while disulfiram, an established drug used to treat alcohol dependence, can form copper-containing complexes with potential anticancer activity. By increasing intracellular copper or changing its distribution, these agents may push metabolically vulnerable tumor cells toward cuproptosis. Nanoparticles and drug-delivery systems are also being investigated as ways to concentrate copper or copper-based compounds within tumors. Such approaches could theoretically improve selectivity, but their safety depends on controlling exposure in the liver, an organ that naturally handles copper and is already vulnerable in patients with cirrhosis or chronic hepatitis.

The opposite strategy is copper deprivation. Chelating agents can bind copper and reduce its availability to cancer cells, potentially suppressing copper-dependent growth, angiogenesis or epithelial–mesenchymal transition, a process associated with invasion and metastasis. This approach could also influence resistance to chemotherapy and radiotherapy. However, copper depletion is not automatically beneficial: normal tissues require copper for essential enzymes, immune function and blood formation. The challenge is to distinguish the copper requirements of a tumor from those of healthy organs. The review therefore presents copper metabolism as a precision-treatment target rather than a simple “more is harmful” or “less is better” system.

The connection between cuproptosis and other forms of regulated cell death may make combination therapy especially powerful. Copper-dependent mitochondrial injury can overlap with oxidative stress, ferroptosis and autophagy. Ferroptosis is driven by iron-dependent lipid peroxidation, whereas cuproptosis centers on copper, lipoylated mitochondrial proteins and proteotoxic stress, but the pathways can interact through glutathione, reactive oxygen species and nutrient metabolism. Studies cited by the authors suggest that disulfiram and copper may consume glutathione and cooperate with suppression of the xCT antioxidant pathway, creating a cascade involving both ferroptosis and cuproptosis. Other experimental work has explored combinations with chemotherapy, radiotherapy, immune-based treatment and engineered nanomaterials. These findings raise the possibility that copper manipulation could sensitize resistant tumors rather than act as a stand-alone therapy.

Yet the field remains far from routine clinical use. Much of the current evidence comes from cell cultures, animal models or retrospective analyses of gene-expression datasets. Cuproptosis-related signatures have been associated with prognosis, immune activity and treatment sensitivity in hepatocellular carcinoma, but a gene-expression pattern is not the same as proof that cuproptosis is occurring in an individual patient. Researchers still need reliable biomarkers showing copper distribution, mitochondrial lipoylation, protein aggregation and pathway activation in living tumors. They must also determine how hypoxia, a common feature of solid cancers, affects treatment response. Recent research indicates that HIF-1α can promote resistance to cuproptosis, suggesting that oxygen availability and metabolic adaptation may decide whether copper-based therapy succeeds. The review concludes that carefully designed clinical studies, improved delivery systems and patient selection will be essential. If those challenges can be solved, copper homeostasis may become more than a biochemical curiosity: it could provide a new route for attacking liver cancer through the very metabolism that allows it to grow.

Subject of Research: Copper homeostasis, cuproptosis, mitochondrial metabolism and therapeutic strategies in hepatocellular carcinoma

Article Title: Cuproptosis in hepatocellular carcinoma: bridging copper homeostasis with therapeutic horizons

Article References: Tsvetkov P, Coy S, Petrova B et al. “Copper induces cell death by targeting lipoylated TCA cycle proteins.” Science 375, 1254–1261 (2022). DOI: 10.1126/science.abf0529; Xing T, Li L, Chen Y et al. “Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma.” Cell Reports Medicine 4, 101264 (2023). DOI: 10.1016/j.xcrm.2023.101264; Fan S, Wang A, Peng R et al. “Cuproptosis in hepatocellular carcinoma: bridging copper homeostasis with therapeutic horizons.” Molecular Biology Reports 53, 1412 (2026).

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12605-0

Keywords: Hepatocellular carcinoma, copper homeostasis, cuproptosis, copper metabolism, mitochondrial metabolism, oxidative stress, ferroptosis, cancer therapy, tumor microenvironment, precision oncology